Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Recruiting

Phase 2

Defactinib, Avutometinib, NivolumabDefactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Sponsor:

Emory University

Code:

NCT06495125

Conditions

Advanced Lung Adenocarcinoma

Refractory Lung Adenocarcinoma

Stage III Lung Cancer AJCC v8

Stage IV Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Avutometinib

Biopsy

Biospecimen Collection

Computed Tomography

Defactinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-09. This information was provided to ClinicalTrials.gov by Emory University on 2026-04-06.